After $3.4B deal and EU withdrawal, Novartis looks to sell Xiidra

Novartis has tapped an adviser to start selling some ophthalmology assets, Bloomberg reports, citing people with knowledge of the matter.

Not all Novartis eye drugs are up for sale. Novartis plans to divest products that treat the front of the eye, the people said, according to Bloomberg. These include Xiidra, a dry eye med that Novartis paid $3.4 billion to get from Takeda, which sold the legacy Shire product in 2019.